Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
Aull
Meredith J
MJ
Division of Transplantation Surgery, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.
Saal
Stuart
S
Dadhania
Darshana
D
Hartono
Choli
C
Kapur
Sandip
S
D000017:ABO Blood-Group System; D000328:Adult; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006683:HLA-DQ Antigens / Q000187:drug effects / Q000276:immunology; D006684:HLA-DR Antigens / Q000187:drug effects / Q000276:immunology; D059845:HLA-DRB4 Chains; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents; D007518:Isoantibodies / Q000097:blood*; D007674:Kidney Diseases / Q000209:etiology / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008297:Male; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D012086:Reoperation; D035781:Siblings; D014019:Tissue Donors; D017211:Treatment Failure
D000017:ABO Blood-Group System; D001897:Boronic Acids; D006680:HLA Antigens; D006683:HLA-DQ Antigens; C053186:HLA-DQ2 antigen; D006684:HLA-DR Antigens; C050610:HLA-DR53; D059845:HLA-DRB4 Chains; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib